Roche’s lung cancer pill beats rivals in head-to-head Phase 3 study
Phase 3positivedivarasibPositive
AI Analysis
Summary
Roche's lung cancer drug divarasib demonstrated a survival benefit over marketed competitors from Amgen and Bristol Myers Squibb in a head-to-head Phase 3 trial. Full data details are pending publication.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
divarasib beat marketed drugs from Amgen and Bristol Myers Squibb in head-to-head trial with survival benefit
Importance:8/10
Sentiment:
0.75
Phase 3 datahead-to-head comparisonlung cancerpositive trial results
Read the original article
Published by Endpoints News on July 2, 2026 11:13 AM